7 investors at Kleiner Perkins, based in Menlo Park, CA with $2.5B under management.
Back to Kleiner Perkins profile
Investor, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Partner, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Principal, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Managing Partner, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Partner, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Partner, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Partner, Kleiner Perkins
James Huang is a venture capital investor at Kleiner Perkins who spent over two decades as an operator in both big pharma and biotech startups before moving into investing, giving him hands-on experience that he draws on to coach portfolio companies on execution and scaling in complex healthcare systems. He specializes in cross-border U.S.-China biotech investments and frequently serves as executive chairman or CEO of portfolio companies and SPAC vehicles, positioning him as both capital provider and hands-on strategic leader in biotech build-outs.
Newsletter
Join thousands of founders and investors. Every Tuesday.